Allakos Inc. (ALLK) Research

Allakos Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapeutic agents. These treatments are designed to target specific immunomodulatory receptors on immune effector cells, addressing a spectrum of allergic, inflammatory, and proliferative conditions. The company's flagship investigational product is lirentelimab (AK002), a monoclonal antibody. This compound is currently undergoing a pivotal Phase III clinical trial for eosinophilic gastritis and/or duodenitis. It is also being evaluated in a Phase II/III study for eosinophilic esophagitis, and a Phase II trial for atopic dermatitis and chronic spontaneous urticaria. Furthermore, Allakos is exploring lirentelimab (AK002) for potential use in mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. In parallel, their pipeline includes AK006, another candidate being developed to tackle various allergic and inflammatory diseases. Established in 2012, Allakos Inc. operates from its headquarters located in Redwood City, California.

Market snapshot

Symbol
ALLK
Price
$0.33
Day change
+0.22%
Market cap
$29.7M
P/E ratio
-1.15x
52-week range
0.22-1.56
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$109.5

Peer companies

  • Applied Genetic Technologies Corporation (AGTC)
  • Angion Biomedica Corp. (ANGN)
  • Elevation Oncology, Inc. (ELEV)
  • Freeline Therapeutics Holdings plc (FRLN)
  • Harpoon Therapeutics, Inc. (HARP)
  • Kineta, Inc. (KA)
  • LianBio (LIANY)
  • Marinus Pharmaceuticals, Inc. (MRNS)

Recent insider activity

  • BVF PARTNERS L P/IL — D-Return (855211 shares) on 2025-05-15
  • Walker Paul Edward — D-Return (3386400 shares) on 2025-05-15
  • Walker Paul Edward — D-Return (37600 shares) on 2025-05-15
  • Walker Paul Edward — D-Return (16000 shares) on 2025-05-15
  • Walker Paul Edward — D-Return (7700 shares) on 2025-05-15

Open Allakos Inc. (ALLK) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.